ALX Oncology (ALXO) announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer, CMO, on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors, where he previously served. An ALX Board member since January 2025, Dr. Klencke has more than 30 years of experience in patient care, academic and scientific research, and clinical drug development in hematology and oncology
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- Alx Oncology’s Earnings Call: Optimism Amidst Challenges
- ALX Oncology doses first patient in Phase 1 trial for ALX2004
- Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump
- ALX Oncology Holdings: Strategic Focus and Promising Developments Drive Buy Rating
- ALX Oncology Advances Cancer Therapy Pipeline